Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 6.95 INR
Change Today +0.30 / 4.51%
Volume 9.1K
INSW On Other Exchanges
Symbol
Exchange
Natl India
As of 7:08 AM 05/4/15 All times are local (Market data is delayed by at least 15 minutes).

ind swift ltd (INSW) Snapshot

Open
6.55
Previous Close
6.65
Day High
7.10
Day Low
6.55
52 Week High
06/11/14 - 12.88
52 Week Low
03/30/15 - 5.16
Market Cap
349.9M
Average Volume 10 Days
11.5K
EPS TTM
11.13
Shares Outstanding
50.3M
EX-Date
09/21/11
P/E TM
0.6x
Dividend
--
Dividend Yield
--
Current Stock Chart for IND SWIFT LTD (INSW)

Related News

No related news articles were found.

ind swift ltd (INSW) Related Businessweek News

No Related Businessweek News Found

ind swift ltd (INSW) Details

Ind-Swift Limited, a pharmaceutical company, manufactures, sells, and exports finished goods dosage and active pharmaceutical ingredients, and herbal products in India and internationally. It has a portfolio of 750 products with presence in therapeutic segments of cardiology, diabetology, anti depressant, anti-allergic, anti-infective, neurology, and oncology. The company's Megaswift division provides medicines for the respiratory inclusive of ENT, chest (anti-tuberculosis), dentistry, anti-infective, cardio-diabetic, and orthopaedic therapies. Its Gyno Swift division offers a range of medicines for gynecology, pediatrics, dermatology, and GP, including gynaecological hormone, anit-haemorroidal, vaginal suppositories, anti-colds, antibiotics, steroids, alkalizsers, oxytocics, vaginal gels, herbal urologicals, anti-flateulents, hameostats, massage oils, anti emetics, antiosteoporotics, vitamins/minerals/nutrients, tocolytics, skin emollients, anti acne, anti-oxidants, cleansers, hepatoprotectants, hair nutritional supplements, melanizing agents, topical antibacterials, demelanizing agents, cosmetics, moisturizers, and cortico-steroid with antibacterials and keratolytics. The company's Generic division provides antibiotic, anti-infectives, anti-colds, nutraceuticals, anti-convulsants, analgesics, anti-diarrhoeal, anti-allergics, anti-inflammatory and anti-ulcer drugs, hypolipidaemic drugs, anti malarial, enzyme, expectorants, antipsychotics, and anti-depressants for treating common ailments, such as fever, cough, cold, diarrhea, body ache, and infections. Its Institutional division provides medicines to government dispensaries, hospitals, and remote and rural areas in India. The company was founded in 1983 and is based in Chandigarh, India.

Founded in 1983

ind swift ltd (INSW) Top Compensated Officers

Chief Executive Officer, Managing Director an...
Total Annual Compensation: 12.0M
Chairman
Total Annual Compensation: 12.0M
Joint Managing Director, Whole Time Director ...
Total Annual Compensation: 12.0M
Compensation as of Fiscal Year 2014.

ind swift ltd (INSW) Key Developments

Ind-Swift Ltd Announces Appointment of Directors

Ind-Swift Ltd. announced that the following have been appointed as Additional Directors on the Board of Directors of the company: Mr. Ashok Gupta (Independent/Non Executive Director), Prof. Veena Dadwal (Independent/Non Executive/Women Director) and Prof. A.D. Ahluwalia (Independent/Non Executive Director.

Ind-Swift Ltd. Reports Unaudited Standalone Earnings Results for the Third Quarter and Nine Months Ended December 31, 2014

Ind-Swift Ltd. reported unaudited standalone earnings results for the third quarter and nine months ended December 31, 2014. For the quarter, the company reported income from operations was INR 662.081 million compared to INR 1,057.829 million a year ago. Loss from operations was INR 439.087 million compared to INR 103.459 million for the same period a year ago. Loss before tax was INR 493.532 million compared to INR 369.956 million for the same period a year ago. Net loss for the period was INR 493.532 million or INR 9.11 per diluted share, compared to INR 369.956 million or INR 8.01 per basic and diluted share, for the same period a year ago. For the year to date, the company reported income from operations was INR 3,383.752 million compared to INR 4,523.708 million a year ago. Loss from operations was INR 749.543 million compared to INR 463.985 million for the same period a year ago. Loss before tax was INR 945.916 million compared to INR 1,203.826 million for the same period a year ago. Net loss for the period was INR 945.916 million or INR 17.46 per diluted share, compared to INR 1,203.826 million or INR 26.07 per basic and diluted share, for the same period a year ago.

Ind-Swift Ltd. to Report Q3, 2015 Results on Feb 13, 2015

Ind-Swift Ltd. announced that they will report Q3, 2015 results on Feb 13, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
INSW:IN 6.95 INR +0.30

INSW Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for INSW.
View Industry Companies
 

Industry Analysis

INSW

Industry Average

Valuation INSW Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.1x
Price/Book 0.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IND SWIFT LTD, please visit www.indswiftltd.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.